Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

ACADIA Pharmaceuticals Inc. - Common Stock (NQ:ACAD)

20.37 -0.22 (-1.07%)
Delayed Quote Updated: 2:53 PM EST, Nov 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about ACADIA Pharmaceuticals Inc. - Common Stock

< Previous 1 2
...
13 14 15 16 17 18 19 20 Next >
News headline image
Acadia Pharmaceuticals to Present at the 11th Annual SVB Leerink Global Healthcare Conference on February 18, 2022
From Acadia Pharmaceuticals Inc.
Via Business Wire
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For February 9, 2022 ↗
Upgrades According to Capital One, the prior rating for Federal Realty Investment Trust (NYSE:FRT) was changed from Equal-Weight to Overweight. Federal Realty Investment... 
Via Benzinga
News headline image
Expert Ratings For ACADIA Pharmaceuticals ↗
ACADIA Pharmaceuticals (NASDAQ:ACAD) has observed the following analyst ratings within the last quarter: 
Via Benzinga
News headline image
Bear Market Bets In Biotech ↗
Taken together, the SPDR S&P Biotech ETF easily broke below the long-term 200-week support for the first time since the pandemic originally hit the markets in March of 2020. 
Via Talk Markets
News headline image
10 Health Care Stocks With Whale Alerts In Today's Session ↗
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our... 
Via Benzinga
News headline image
Acadia, Stoke Team Up In $900M+ Deal On RNA Therapies For CNS Disorders ↗
Acadia Pharmaceuticals Inc (NASDAQ: ACAD) and Stoke Therapeutics Inc (NASDAQ: STOK) will team up on the treatments in rare genetic neurodevelopmental diseases of... 
Via Benzinga
News headline image
Acadia Pharmaceuticals and Stoke Therapeutics Announce Collaboration to Pursue Multiple RNA-based Treatments for Severe and Rare Genetic Neurodevelopmental Diseases
From Acadia Pharmaceuticals Inc.
Via Business Wire
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For January 5, 2022 ↗
Upgrades According to TD Securities, the prior rating for Canada Goose Holdings Inc (NYSE: 
Via Benzinga
News headline image
What 17 Analyst Ratings Have To Say About ACADIA Pharmaceuticals ↗
Analysts have provided the following ratings for ACADIA Pharmaceuticals (NASDAQ: 
Via Benzinga
News headline image
$1000 Invested In This Stock 10 Years Ago, Would Be Worth This Much ↗
ACADIA Pharmaceuticals (NASDAQ:ACAD) has outperformed the market over the past 10 years by 22.05% on an annualized basis. Buying $1,000 In ACAD: 10 years ago, an investor could... 
Via Benzinga
News headline image
5 Beaten Down Biotech Stocks That Could Bounce Big In 2022 ↗
Biotech stocks remain poised to eke out modest gains for 2021 after the stellar gains of the previous year. COVID-19 drug and vaccine developers experienced volatility throughout... 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Thursday's After-Market Session ↗
Gainers Tempest Therapeutics (NASDAQ:TPST... 
Via Benzinga
News headline image
Acadia Pharmaceuticals to Present at the 40th Annual J.P. Morgan Healthcare Conference on January 11, 2022
From Acadia Pharmaceuticals Inc.
Via Business Wire
News headline image
55 Biggest Movers From Yesterday ↗
Gainers Reliance Global Group, Inc. (NASDAQ: RELI) shares jumped 78.7% to close at $5.45 on Tuesday after gaining around 6% on Monday. Biofrontera Inc. (NASDAQ: BFRI) gained 44.8... 
Via Benzinga
News headline image
What Analysts Have To Say On Acadia's Narrower Nuplazid Label Expansion Bid ↗
RBC Capital 
Via Benzinga
News headline image
Acadia Slims Nuplazid Label Expansion Application For Alzheimer's Disease Psychosis ↗
After suffering rejection from the FDA in April, Acadia Pharmaceuticals Inc (NASDAQ: ACAD) is making another bid to expand the scope of its Parkinson's disease... 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Tuesday's Intraday Session ↗
Gainers Jaguar Health (NASDAQ:JAGX) shares increased by 58.26% to $1.82 during Tuesday's regular session. Trading volume for this security as of 12:30 EST is 28.4... 
Via Benzinga
News headline image
38 Stocks Moving In Tuesday's Mid-Day Session ↗
Gainers Reliance Global Group, Inc. (NASDAQ: RELI) surged 126% to $6.91 after gaining around 6% on Monday. Biofrontera Inc. (NASDAQ: BFRI) climbed 71.4% to $13.06 after gaining... 
Via Benzinga
News headline image
Why This Acadia Pharmaceuticals Move Has Analysts Split — And Shares Down 20% ↗
After a rejection in April, Acadia is planning to ask for approval in Alzheimer's patients. 
Via Investor's Business Daily
News headline image
The Daily Biotech Pulse: Aldeyra Sinks On Dry Eye Disease Readout, Sanofi Goes Shopping, Regulatory Setback For Aquestive, Aridis Touts Pan-Coronavirus Antibody Cocktail ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus CytomX Mid-Phase Study Of ADC In Lung And Head & Neck Cancer Patients... 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Monday's After-Market Session ↗
Gainers ACADIA Pharmaceuticals (NASDAQ:ACAD 
Via Benzinga
News headline image
Acadia Pharmaceuticals Announces Plan for a Resubmission of its Supplemental New Drug Application to U.S. FDA for NUPLAZID® (pimavanserin)
From Acadia Pharmaceuticals Inc.
Via Business Wire
News headline image
Top Biotech Stocks: Trading Opportunities For Next Week ↗
A security pattern traces the distinct movements of prices, which helps traders make informed trading decisions. Let's look at some biotech stock opportunities by analyzing these patterns. 
Via Talk Markets
News headline image
Acadia Pharmaceuticals Announces Promotion of Mark Schneyer to Executive Vice President, Chief Financial Officer
From Acadia Pharmaceuticals Inc.
Via Business Wire
News headline image
What 7 Analyst Ratings Have To Say About ACADIA Pharmaceuticals ↗
Over the past 3 months, 7 analysts have published their opinion on ACADIA Pharmaceuticals (NASDAQ: 
Via Benzinga
News headline image
Why Acadia Pharmaceuticals Stock Is Rocketing Today ↗
A positive clinical readout is lighting a fire underneath the biotech's shares today. 
Via The Motley Fool
News headline image
The Daily Biotech Pulse: Acadia Jumps On Data, vTv Shelves Psoriasis Study, More Setbacks For Merck's HIV Program, Decision Day For Daré ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Acadia Announces Positive Phase 3 Data For Trofinetide In Rett Syndrome... 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗
Gainers ACADIA Pharmaceuticals (NASDAQ:ACAD) stock rose 18.35% to $22.96 during Tuesday's pre-market session. The company's market cap stands at $3.6 billion.... 
Via Benzinga
News headline image
10 Biggest Price Target Changes For Tuesday ↗
Oppenheimer cut the price target on Coupa Software Incorporated (NASDAQ: 
Via Benzinga
News headline image
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday ↗
Good morning, trader! We're beginning another busy day of trading with a breakdown of the biggest pre-market stock movers for Tuesday! 
Via InvestorPlace
< Previous 1 2
...
13 14 15 16 17 18 19 20 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.